Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

Open access
Fensome, Andrew, Ambler, Catherine M., Arnold, Eric, Banker, Mary Ellen, Brown, Matthew F., Chrencik, Jill, Clark, James D., Dowty, Martin E., Efremov, Ivan V., Flick, Andrew, Gerstenberger, Brian S., Gopalsamy, Ariamala, Hayward, Matthew M., Hegen, Martin, Hollingshead, Brett D., Jussif, Jason, Knafels, John D., Limburg, David C., Lin, David, Lin, Tsung H., Pierce, Betsy S., Saiah, Eddine, Sharma, Raman, Symanowicz, Peter T., Telliez, Jean-Baptiste, Trujillo, John I., Vajdos, Felix F., Vincent, Fabien, Wan, Zhao-Kui, Xing, Li, Yang, Xiaojing, Yang, Xin, Zhang, Liying · 2018 · Journal of Medicinal Chemistry

Abstract

Cytokine signaling is an important characteristic of autoimmune diseases. Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway. JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6, and type-I interferon (IFN) family, while TYK2 in addition to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling. Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease, and rheumatoid arthritis studies, leading to multiple drug approvals. We hypothesized that a dual JAK1/TYK2 inhibitor will provide additional efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes. Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compound 23), which is in Phase II clinical development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b00917

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 178

Metadata

Authors
Fensome, A., Ambler, C. M., Arnold, E., Banker, M. E., Brown, M. F., Chrencik, J., Clark, J. D., Dowty, M. E., Efremov, I. V., Flick, A., Gerstenberger, B. S., Gopalsamy, A., Hayward, M. M., Hegen, M., Hollingshead, B. D., Jussif, J., Knafels, J. D., Limburg, D. C., Lin, D., Lin, T. H., Pierce, B. S., Saiah, E., Sharma, R., Symanowicz, P. T., Telliez, J.-B., Trujillo, J. I., Vajdos, F. F., Vincent, F., Wan, Z.-K., Xing, L., Yang, X., Yang, X., & Zhang, L.
Venue
Journal of Medicinal Chemistry
Published
2018-08-16
Volume
61
Issue
19
Pages
8597-8612
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2887542285
Cited by
178
References
4
FWCI
4.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b00917
The paper
Fensome, A., Ambler, C. M., Arnold, E., Banker, M. E., Brown, M. F., Chrencik, J., Clark, J. D., Dowty, M. E., Efremov, I. V., Flick, A., Gerstenberger, B. S., Gopalsamy, A., Hayward, M. M., Hegen, M., Hollingshead, B. D., Jussif, J., Knafels, J. D., Limburg, D. C., Lin, D., . . . Zhang, L. (2018). Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b00917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.